Disrupting the EGFR-T790M/MYH9/β-actin signaling axis enhances the therapeutic efficacy of CL-387,785 (a kinase inhibitor for EGFR-T790M) against drug-resistant NSCLC cells [214]. Here, MYH9 is linked to non-small cell lung carcinoma.